Busca avançada
Ano de início
Entree
(Referência obtida automaticamente do Web of Science, por meio da informação sobre o financiamento pela FAPESP e o número do processo correspondente, incluída na publicação pelos autores.)

Drugs in early clinical development for Systemic Lupus Erythematosus

Texto completo
Autor(es):
Postal, Mariana [1] ; Sinicato, Nailu Angelica [1] ; Appenzeller, Simone [1] ; Niewold, Timothy B. [2]
Número total de Autores: 4
Afiliação do(s) autor(es):
[1] Univ Estadual Campinas, Dept Med, Rheumatol Unit, Fac Med Sci, Campinas, SP - Brazil
[2] Mayo Clin, Dept Immunol, Div Rheumatol, 200 1st St Southwest, Guggenheim Bldg 3-42, Rochester, MN 55905 - USA
Número total de Afiliações: 2
Tipo de documento: Artigo de Revisão
Fonte: EXPERT OPINION ON INVESTIGATIONAL DRUGS; v. 25, n. 5, p. 573-583, MAY 2016.
Citações Web of Science: 7
Resumo

Introduction: While immunosuppressive therapy has positively impacted the prognosis of systemic lupus erythematosus (SLE), many patients still do not respond to traditional therapy. Thus, active SLE disease remains a significant problem. Furthermore, conventional immunosuppressive treatments for SLE are associated a high risk of side effects. These issues call for improvement in our current therapeutic armamentarium.Areas covered: In this review, the authors highlight the recent developments in therapies for SLE, and present an overview of drugs which are in early clinical development for SLE. There are many new therapeutic approaches being developed, including those focused on B-cell targets, T-cell downregulation, co-stimulatory blockade, anti-cytokine agents, and kinase inhibition, and Toll-like receptor inhibition. They also discuss peptide therapy as a potential method to re-establish immune tolerance, and some of the challenges ahead in developing and testing novel agents for SLE.Expert opinion: Many novel agents are currently in development for SLE, but this encouraging news is tempered by several disappointments in clinical trials and provides a timely moment to reflect on the future of therapeutic development in SLE. It seems likely that biological heterogeneity between patients is a major contributor to difficulty in drug design in SLE. (AU)

Processo FAPESP: 09/06049-6 - Determinação de marcadores séricos e do líquor associados a alterações estruturais e funcionais do sistema nervoso central no Lúpus eritematoso sistêmico
Beneficiário:Simone Appenzeller
Linha de fomento: Bolsas no Brasil - Apoio a Jovens Pesquisadores
Processo FAPESP: 09/15286-1 - Prevalência e fatores associados à síndrome metabólica no lúpus eritematoso sistêmico juvenil
Beneficiário:Nailú Angélica Sinicato Martin
Linha de fomento: Bolsas no Brasil - Iniciação Científica
Processo FAPESP: 08/02917-0 - Determinação de marcadores séricos e do líquor associados a alterações estruturais e funcionais do sistema nervoso central no lúpus eritematoso sistêmico
Beneficiário:Simone Appenzeller
Linha de fomento: Auxílio à Pesquisa - Apoio a Jovens Pesquisadores